Navigation
banner

Responding to Emerging Infectious Diseases on the Global Stage

GTCbio | March 13th, 2017

In recent years, a handful of both naturally occurring and human-driven infectious disease threats and public health emergencies have surfaced. However, managing these infectious disease outbreaks effectively and efficiently have made it difficult for responders due to the unpredictable nature of these diseases. Nationally and globally led efforts are directed towards rapid response to such outbreaks and consequently, we can look forward to lessons learned to continually ensure global health security.

The joint plenary session “Responding to Emerging Infectious Diseases on the Global Stage” at GTCbio’s Infectious Diseases Summit will be showcasing the following speakers from institutes/companies that respond to emerging infectious diseases. This summit will be held at the Royal Sonesta Harbor Court Baltimore on July 13-14, 2017 in Baltimore, MD.  

  • Heinz Feldmann, Chief, Laboratory of Virology & Disease Modeling and Transmission, NIAID, NIH

    Heinz Feldmann is the laboratory expert on high containment viruses (BSL4) and serves as a consultant on viral hemorrhagic fevers and related pathogens for the World Health Organization and, thus, has field experience and expertise in outbreak management.
  • Michael Osterholm, Regents Professor and Director, Center for Infectious Disease Research and Policy, University of Minnesota

    As he has done in his recently published book, Deadliest Enemy: Our War Against Killer Germs, Dr. Osterholm shows us how we could wake up to a reality in which many antibiotics no longer cure, bioterror is a certainty, and the threat of a disastrous influenza pandemic looms ever larger. His talk will discuss programs to keep ourselves safer from infectious disease.
     
  • David Vaughn, Senior Vaccine Development Leader for Influenza and Dengue Vaccines, GSK Vaccines Research and Development

    GSK’s vaccines business is one of the largest in the world, developing, producing and distributing over 1.9 million vaccine doses every day for use in 90% of the world’s countries. David Vaughn’s talk will detail GSK’s proposal to create a biopreparedness organization or BPO to continuously design and develop vaccines against previously identified and newly occurring pathogens that present a threat to global health.
     
  • Brent Korba, Professor, Georgetown University

    Noroviruses (NoV) are the leading cause of nonbacterial, acute gastroenteritis worldwide and pose a significant financial burden (>$5B) on U.S. healthcare systems. Dr. Korba will discuss antiviral development for NoV infections in its infancy while providing an especially significant opportunity for the development of therapeutic agents.

We invite you to join us at GTCbio’s Infectious Diseases Summit, which consists of three co-located conferences: 

  1. 15th Vaccines Research & Development will focus on defining emerging global health threats (Zika, multi-drug resistant TB, influenza), discussing next generation technologies to address these foes (novel adjuvants, DC vaccines, nucleic acid vaccines, recombinant viral vectors) and addressing challenges to those goals.

  2. 14th Anti-Infectives Partnering & Deal-Making: highlights the types and availability of economic incentives to spur innovation and development of therapies to address rapidly emerging global health threats, international partnering and funding opportunities, and non-traditional approaches and technologies, including innovative clinical trial strategies for the development of anti-infectives.

  3. 6th Antiviral Drugs Research & Development emphasizes current landscape and emerging new therapies in the field of HIV, RSV, Hepatitis B/C, Influenza etc. New drug designs and their mechanism of actions, approaches to address immune evasion mechanisms and viral resistance, and challenges in clinical study designs will also be discussed.